Your browser doesn't support javascript.
loading
Neonatal invasive pneumococcal disease: New Zealand experience in the era of pneumococcal vaccination.
Mount, Vicki; Burton, Cameron; Jackson, Catherine; Heffernan, Helen; Best, Emma.
Afiliação
  • Mount V; Department of Paediatrics, University of Auckland, Auckland, New Zealand.
  • Burton C; Starship Children's Health, Auckland District Health Board, Auckland, New Zealand.
  • Jackson C; Auckland Regional Public Health Service, Auckland District Health Board, Auckland, New Zealand.
  • Heffernan H; Institute of Environmental Science and Research (ESR), Kenepuru Science Centre, Porirua, New Zealand.
  • Best E; Department of Paediatrics, University of Auckland, Auckland, New Zealand.
Aust N Z J Obstet Gynaecol ; 57(3): 280-285, 2017 Jun.
Article em En | MEDLINE | ID: mdl-27530965
ABSTRACT

BACKGROUND:

Invasive pneumococcal disease (IPD) became a notifiable disease in New Zealand in 2008, and in the same year pneumococcal conjugate vaccine (PCV) was added to the childhood immunisation schedule.

DESIGN:

This was a retrospective study of IPD in infants aged <90 days reported to the national notifiable disease database, EpiSurv, from 1 January 2009 to 31 December 2013. All cases had Streptococcus pneumoniae isolated from a normally sterile site. MAIN OUTCOME

MEASURES:

IPD incidence was calculated for babies aged <90 and <30 days using the number of national IPD cases with a denominator of annual infant live births. Clinical, demographic and outcome data were reviewed for infants aged less than seven days (early onset).

RESULTS:

There were 29 cases of IPD in infants aged <90 days and 19 cases in infants aged <30 days. Of the nine early-onset cases, six occurred within the first 48 h. Six of the early-onset cases were infants of NZ Maori ethnicity. One infant died six hours after birth. Three infants developed long-term neurological or respiratory sequelae. Isolates from five of the early-onset cases were S. pneumoniae serotypes not covered by the PCV in use at the time of infection. Maternal vaccination with 23-valent pneumococcal vaccine would have covered 84% (16 of 19) of serotypes responsible for the cases in infants <30 days old.

CONCLUSION:

Strategies such as maternal vaccination or accelerated neonatal vaccination may be beneficial to protect neonates at high risk of IPD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Pneumocócica / Vacinação / Vacinas Pneumocócicas / Meningite Pneumocócica Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans / Infant / Newborn País/Região como assunto: Oceania Idioma: En Revista: Aust N Z J Obstet Gynaecol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Nova Zelândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Pneumocócica / Vacinação / Vacinas Pneumocócicas / Meningite Pneumocócica Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans / Infant / Newborn País/Região como assunto: Oceania Idioma: En Revista: Aust N Z J Obstet Gynaecol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Nova Zelândia